In a Nov. 5 update, Research Capital analyst André Uddin reiterated his “Speculative Buy” rating and C$12.00 target price for Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX), saying the company’s near-term focus remains on advancing its lead candidate EP-104GI in eosinophilic esophagitis while awaiting upcoming clinical readouts. Uddin said Eupraxia reported […]
Leede Financial has initiated coverage of Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials NASDAQ:EPRX), assigning a “Buy” rating and a US $11.00 target price. Analyst Douglas Loe said the Victoria, B.C.-based biotechnology company’s proprietary drug-delivery platform positions it to “innovate meaningfully in autoimmune and inflammatory disease markets,” led by late-stage programs in […]
Share
Tweet
Share
